Advances In™ Prevention and Treatment of Large Hemispheric Infarction (LHI)
September 30, 2019
September 30, 2020
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
Supported by an educational grant from Biogen.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — maximum of 1.0 contact hours
All other health care professionals completing this course will be issued a statement of participation.
This online educational activity is directed toward neurologists, cardiologists, emergency department physicians, internists, primary care physicians, physician assistants, nurse practitioners, nurses, and other healthcare professionals involved in patient care for prevention and treatment of stroke.
Stroke is a main contributor of morbidity and mortality in western populations. It can result in serious long-term disability. Individuals with a more catastrophic large hemispheric infarction (LHI) may progress to brain death within 2 to 5 days, and survivors are likely to be severely disabled with poor quality of life. With the advent of new therapies for the prevention and treatment of LHI, it is critical that clinicians be educated on all aspects of the disorder, including earlier identification and diagnostic methods, effective assessment and stratification of risk factors, and current treatment options. A larger emphasis of this curriculum is on updating clinicians on novel advancements in the treatment of cerebral edema following an LHI, with an emphasis on improving clinicians’ knowledge regarding clinical management, including developments in clinical research and treatment guidelines.
Benefits of Participating
- Learn about strategic measures to improve on care of patients at risk of stroke, including ways to improve patient education about self-care strategies that may reduce the risk
- Increase awareness of guideline recommendations for treatment of patients who have suffered an acute ischemic stroke or large hemispheric infarct
- Learn about best practices to enhance clinical decision making when choosing among treatment options available for patients who are at risk of cerebral edema following a large hemispheric infarct
Upon completion of this activity, participants should be able to:
- Review the neurologic assessment of acute ischemic stroke and early recognition of prognostic factors for large hemispheric infarction (LHI)
- Discuss primary and secondary prevention for acute ischemic stroke
- Assess current gaps and limitations in care of acute ischemic stroke and LHI
- Evaluate clinical trial safety and efficacy for treatment of patients with LHI
Kevin N. Sheth, MD
Professor, Department of Neurology and Neurosurgery
Yale University School of Medicine
Division Chief, Neurocritical Care and Emergency Neurology
Associate Chair, Clinical Research, Department of Neurology
Director, Neurosciences Intensive Care Unit
Yale New Haven Hospital
New Haven, CT
Gregory W. Albers, MD
Director, Stanford Stroke Center
Stanford Medical Center
Professor of Neurology
Palo Alto, CA
Physician Accreditation Statement
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians
Physician Credit Designation
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Disclosures of Conflicts of Interest
Kevin N. Sheth, MD
- Grant/Research Support: National Institutes of Health, American Heart Association, Biogen, Novartis, Bard, Hyperfine
- Data Safety Monitoring Board: Zoll
- Other: Alva, Astrocyte
Gregory W. Albers, MD
- Consultant: Biogen
PER uses a blinded peer review process.
The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.
The peer reviewer discloses the following:
- Grant Research Support:: NINDS
- Consultant:: Remedy Pharmaceuticals, Biogen
- Shareholder:: Remedy Pharmaceuticals.
Method of Participation
Instructions for This Activity and Receiving Credit
- You will need to log in to participate in the activity.
- Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
- At the end of the activity, educational content/audio files will be available for your reference.
- In order to receive a CME/CE certificate, you must complete the activity.
- Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.
Disclosure of Unlabeled Use
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or the company that provided commercial support for this program.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.